First being lung volume reduction surgery (LVRS) which carries significant higher risk of mortality within 90 days of the procedure versus bronchoscopic lung volume reduction surgery (BLVR). BLVR has reduced peri-operative morbidity without compromising the long-term effect of improvement in post-...
As stated in the Summary of Safety and Effectiveness Data, the FDA granted the Zephyr Valve an expedited review because it “represents a breakthrough technology as the device offers bronchoscopic lung volume reduction without surgery and its associated risks. This device offers significant clinically ...